vs
Side-by-side financial comparison of Alarm.com Holdings, Inc. (ALRM) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
Alarm.com Holdings, Inc. is the larger business by last-quarter revenue ($261.7M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). Alarm.com Holdings, Inc. runs the higher net margin — 13.2% vs 11.1%, a 2.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 8.0%). Alarm.com Holdings, Inc. produced more free cash flow last quarter ($35.1M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 8.3%).
Alarm.com, Inc. is an American technology company that provides cloud-based services for remote control, home automation, and alarm monitoring services. The company was founded in 2000 as a spinoff from MicroStrategy. The company is based in Tysons, Virginia.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ALRM vs ANIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $261.7M | $247.1M |
| Net Profit | $34.6M | $27.5M |
| Gross Margin | 66.0% | — |
| Operating Margin | 13.4% | 14.1% |
| Net Margin | 13.2% | 11.1% |
| Revenue YoY | 8.0% | 29.6% |
| Net Profit YoY | 14.8% | 367.5% |
| EPS (diluted) | $0.66 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $261.7M | $247.1M | ||
| Q3 25 | $256.4M | $227.8M | ||
| Q2 25 | $254.3M | $211.4M | ||
| Q1 25 | $238.8M | $197.1M | ||
| Q4 24 | $242.2M | $190.6M | ||
| Q3 24 | $240.5M | $148.3M | ||
| Q2 24 | $233.8M | $138.0M | ||
| Q1 24 | $223.3M | $137.4M |
| Q4 25 | $34.6M | $27.5M | ||
| Q3 25 | $35.1M | $26.6M | ||
| Q2 25 | $34.2M | $8.5M | ||
| Q1 25 | $27.7M | $15.7M | ||
| Q4 24 | $30.1M | $-10.3M | ||
| Q3 24 | $36.7M | $-24.2M | ||
| Q2 24 | $33.5M | $-2.3M | ||
| Q1 24 | $23.6M | $18.2M |
| Q4 25 | 66.0% | — | ||
| Q3 25 | 65.8% | — | ||
| Q2 25 | 65.6% | — | ||
| Q1 25 | 67.2% | — | ||
| Q4 24 | 65.5% | — | ||
| Q3 24 | 64.8% | — | ||
| Q2 24 | 65.2% | — | ||
| Q1 24 | 65.7% | — |
| Q4 25 | 13.4% | 14.1% | ||
| Q3 25 | 14.4% | 15.9% | ||
| Q2 25 | 12.6% | 6.6% | ||
| Q1 25 | 12.4% | 13.3% | ||
| Q4 24 | 12.7% | -2.3% | ||
| Q3 24 | 13.8% | -13.8% | ||
| Q2 24 | 11.0% | 3.7% | ||
| Q1 24 | 8.4% | 14.8% |
| Q4 25 | 13.2% | 11.1% | ||
| Q3 25 | 13.7% | 11.7% | ||
| Q2 25 | 13.5% | 4.0% | ||
| Q1 25 | 11.6% | 8.0% | ||
| Q4 24 | 12.4% | -5.4% | ||
| Q3 24 | 15.3% | -16.3% | ||
| Q2 24 | 14.3% | -1.7% | ||
| Q1 24 | 10.6% | 13.2% |
| Q4 25 | $0.66 | $1.14 | ||
| Q3 25 | $0.65 | $1.13 | ||
| Q2 25 | $0.63 | $0.36 | ||
| Q1 25 | $0.52 | $0.69 | ||
| Q4 24 | $0.56 | $-0.45 | ||
| Q3 24 | $0.67 | $-1.27 | ||
| Q2 24 | $0.62 | $-0.14 | ||
| Q1 24 | $0.44 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $960.6M | $285.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $848.2M | $540.7M |
| Total Assets | $2.1B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $960.6M | $285.6M | ||
| Q3 25 | $1.1B | $262.6M | ||
| Q2 25 | $1.0B | $217.8M | ||
| Q1 25 | $1.2B | $149.8M | ||
| Q4 24 | $1.2B | $144.9M | ||
| Q3 24 | $1.2B | $145.0M | ||
| Q2 24 | $1.1B | $240.1M | ||
| Q1 24 | $747.9M | $228.6M |
| Q4 25 | $848.2M | $540.7M | ||
| Q3 25 | $827.2M | $505.8M | ||
| Q2 25 | $797.3M | $436.8M | ||
| Q1 25 | $759.6M | $418.6M | ||
| Q4 24 | $726.5M | $403.7M | ||
| Q3 24 | $690.3M | $405.9M | ||
| Q2 24 | $645.5M | $455.8M | ||
| Q1 24 | $728.1M | $452.0M |
| Q4 25 | $2.1B | $1.4B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.0B | $1.3B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $1.9B | $920.8M | ||
| Q1 24 | $1.5B | $914.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $30.4M |
| Free Cash FlowOCF − Capex | $35.1M | $29.1M |
| FCF MarginFCF / Revenue | 13.4% | 11.8% |
| Capex IntensityCapex / Revenue | 0.3% | 0.5% |
| Cash ConversionOCF / Net Profit | 1.04× | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | $137.0M | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $30.4M | ||
| Q3 25 | $70.6M | $44.1M | ||
| Q2 25 | $22.7M | $75.8M | ||
| Q1 25 | $24.1M | $35.0M | ||
| Q4 24 | $56.3M | $15.9M | ||
| Q3 24 | $77.3M | $12.5M | ||
| Q2 24 | $23.0M | $17.4M | ||
| Q1 24 | $49.9M | $18.3M |
| Q4 25 | $35.1M | $29.1M | ||
| Q3 25 | $65.9M | $38.0M | ||
| Q2 25 | $18.2M | $71.8M | ||
| Q1 25 | $17.9M | $32.5M | ||
| Q4 24 | $54.0M | $13.5M | ||
| Q3 24 | $74.5M | $7.7M | ||
| Q2 24 | $21.0M | $13.0M | ||
| Q1 24 | $46.8M | $13.7M |
| Q4 25 | 13.4% | 11.8% | ||
| Q3 25 | 25.7% | 16.7% | ||
| Q2 25 | 7.1% | 34.0% | ||
| Q1 25 | 7.5% | 16.5% | ||
| Q4 24 | 22.3% | 7.1% | ||
| Q3 24 | 31.0% | 5.2% | ||
| Q2 24 | 9.0% | 9.4% | ||
| Q1 24 | 21.0% | 10.0% |
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 1.9% | 2.7% | ||
| Q2 25 | 1.8% | 1.9% | ||
| Q1 25 | 2.6% | 1.3% | ||
| Q4 24 | 0.9% | 1.3% | ||
| Q3 24 | 1.2% | 3.2% | ||
| Q2 24 | 0.9% | 3.2% | ||
| Q1 24 | 1.4% | 3.3% |
| Q4 25 | 1.04× | 1.10× | ||
| Q3 25 | 2.01× | 1.66× | ||
| Q2 25 | 0.66× | 8.87× | ||
| Q1 25 | 0.87× | 2.23× | ||
| Q4 24 | 1.87× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 2.11× | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALRM
| License And Service | $180.2M | 69% |
| Hardwareand Other Revenue | $81.4M | 31% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
